Longboard Pharmaceuticals, Inc., (LBPH): Price and Financial Metrics
GET POWR RATINGS... FREE!
LBPH Stock Price Chart Interactive Chart >
LBPH Price/Volume Stats
| Current price | $4.26 | 52-week high | $6.47 |
| Prev. close | $4.40 | 52-week low | $2.70 |
| Day low | $4.18 | Volume | 41,736 |
| Day high | $4.38 | Avg. volume | 26,092 |
| 50-day MA | $4.70 | Dividend yield | N/A |
| 200-day MA | $4.17 | Market Cap | 57.88M |
Longboard Pharmaceuticals, Inc., (LBPH) Company Bio
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. The company was founded in 2020 and is based in San Diego, California.
Latest LBPH News From Around the Web
Below are the latest news stories about LONGBOARD PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LBPH as an investment opportunity.
Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy VolunteersLA JOLLA, Calif., December 05, 2022--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced positive topline results from a Phase 1 clinical study evaluating the central nervous system (CNS) pharmacokinetics (PK) and pharmacodynamics (PD) of LP352, an oral, centrally acting 5-HT2C superagonist, in healthy volunteers. |
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy CommunityLongboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of developmental and epileptic encephalopathies (DEEs), in two poster |
Longboard Pharmaceuticals: Arena''s Next Act Flying Under RadarLongboard Pharmaceuticals is a Buy. Key concerns include near term dilution, binary risk as a single drug story and low trading volume. Read my analysis on LBPH. |
Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology DayLA JOLLA, Calif., November 08, 2022--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present in a fireside chat format at the Guggenheim Healthcare Talks 4th Annual Immunology and Neurology Day, which is taking place November 14-15, 2022, in New York City. |
Longboard Pharmaceuticals: Q3 Earnings InsightsLongboard Pharmaceuticals (NASDAQ: LBPH ) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here''s what investors need to know about the announcement. Earnings Longboard Pharmaceuticals missed estimated earnings by 6.25%, reporting an EPS of … Full story available on Benzinga.com |
LBPH Price Returns
| 1-mo | 30.67% |
| 3-mo | 12.70% |
| 6-mo | 20.34% |
| 1-year | 1.43% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 30.67% |
| 2022 | -33.20% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...